stockrow
Saturday 7 November 2026
Export ALDX’s income statement to Excel — free account
Aldeyra Therapeutics, Inc.
ALDX Healthcare Biotechnology
- EPS
- +43.8%
- Free cash flow
- +46.1%
- Total debt
- +1.33%
Quarter to June 2026, against a year earlier
0.64
0.02
+3.23%
Follow ALDX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 7 | 7 | 27 | +99.6% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (19) | (22) | (39) | (62) | (38) | (58) | (62) | (38) | (56) | (34) | (23) | +6.8% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (19) | (22) | (39) | (61) | (38) | (58) | (62) | (38) | (56) | (34) | (23) | +6.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (1.65) | (1.40) | (1.79) | (2.24) | (1.11) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) | (0.39) | (11.3%) | ||||||
| Cash flow | (1.33) | (1.21) | (1.38) | (1.66) | (1.10) | (0.79) | (0.97) | (0.51) | (0.73) | (0.56) | (0.37) | (9.3%) | ||||||
| Capex | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (1.34) | (1.21) | (1.39) | (1.66) | (1.10) | (0.79) | (0.97) | (0.51) | (0.73) | (0.56) | (0.37) | (9.3%) | ||||||
| Book value | 1.91 | 2.49 | 3.99 | 1.77 | 1.75 | 3.81 | 2.59 | 2.03 | 1.19 | 0.74 | 0.63 | (10.0%) | ||||||
| Shares, m | 11 | 16 | 22 | 27 | 34 | 54 | 58 | 59 | 59 | 60 | 60 | +20.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (15) | (19) | (30) | (45) | (37) | (43) | (57) | (30) | (43) | (33) | (22) | +9.2% | |||||
| Capex | 0 | 0 | 0 | 0 | — | 0 | 0 | — | — | — | 0 | +5.5% | ||||||
| Free cash flow | (15) | (19) | (30) | (45) | (37) | (43) | (57) | (30) | (43) | (33) | (22) | +9.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 23 | 41 | 86 | 62 | 71 | 221 | 166 | 126 | 85 | 44 | 38 | +7.6% | |||||
| Net debt | (24) | (42) | (94) | (59) | (63) | (214) | (158) | (128) | (86) | (55) | (45) | +9.8% | ||||||
| Shareholders’ equity | 22 | 40 | 87 | 48 | 60 | 206 | 151 | 120 | 71 | 44 | 38 | +8.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (70.05) | (64.42) | (55.85) | (71.31) | (47.28) | (36.51) | (29.93) | (22.78) | (44.16) | (38.32) | (34.80) | +31.7 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (80.38) | (72.95) | (61.63) | (90.31) | (69.81) | (43.56) | (34.77) | (27.73) | (58.54) | (58.73) | (49.48) | +21.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 11 | 12 | 19 | 20 | 11 | 12 | 15 | 10 | 9 | 8 | — | (3.5%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Aldeyra Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| DWTX Dogwood Therapeutics, Inc | $39.8M | — (loss-making) | — | — | n/m | +10.31% (above 0%: growing) | — | 0.00% | Compare |
| EXOZ eXoZymes Inc. | $38.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | Compare |
| IBO Impact Biomedical Inc. | $38.0M | — (loss-making) | — | −57.14% (below 0%: shrinking) | n/m | +167.72% (above 0%: growing) | 66.67% | (23,400.00%) | Compare |
| ELTX Elicio Therapeutics, Inc. | $37.9M | — (loss-making) | — (loss-making) | −55.27% (below 0%: shrinking) | n/m | +8.77% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRCE Grace Therapeutics, Inc. | $37.5M | — (loss-making) | — (loss-making) | +5,127.27% (above 0%: growing) | n/m | −78.85% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALDX Aldeyra Therapeutics, Inc. | $37.2M | — (loss-making) | — | — | n/m | +46.09% (above 0%: growing) | 0.00% | 0.00% | |
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| VERU Veru Inc. | $35.1M | — (loss-making) | — (loss-making) | +99.23% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 67.84% | 0.00% | Compare |
| Median of peers | $37.7M | — | — | +21.98% | — | +3.03% | 66.67% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 4.70m | 4.29m | 74.43 |
| 2024 | 3.93m | 6.05m | 71.70 |
| 2023 | 3.68m | (1.22m) | 50.43 |
Ownership
Directors and executive officers, together
11.80%
Perceptive Advisors LLC
6.90%
Todd C. Brady, M.D., Ph.D.
6.80%
Knoll Capital Management, LLC
6.00%
BlackRock, Inc.
5.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement